EyeTect: Starting Over with OMT for Neuro Intensive Care
Executive Summary
For its first three years, EyeTect, developers of an innovative technology using ocular microtremors to monitor brain function, was the very model of efficient device development. With less than $1 million raised, the company developed a working device, funded several important clinical studies, and even got FDA clearance. But when an anticipated marketing agreement with a well-established competitor fell through, the company all but shut down. Now EyeTect is starting again, with a new managment team and a new target application.
You may also be interested in...
Rethinking Alzheimer's: Mapping Out an Approval Process
Drug companies involved in Alzheimer's disease research are a little fed up with FDA. Some, like Wyeth, believe the agency should put Alzheimer's research higher up on its priority list and allow the use of surrogate endpoints for clinical trials. But FDA says that no validated surrogate exists for Alzheimer's, and until it has hard data from products in development, it is loath to recommend one. A recent reorganization of the agency's neurology group may provide an opening to press home those arguments.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.